|
Jul 17
|
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
|
|
Jul 16
|
Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet
|
|
Jun 18
|
Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit
|
|
May 10
|
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
|
|
May 10
|
Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
|
|
May 9
|
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
|
|
May 9
|
Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?
|
|
May 3
|
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
|
|
May 2
|
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Apr 25
|
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
|
|
Apr 23
|
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
|
|
Apr 19
|
Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
|
|
Apr 4
|
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
|
|
Apr 4
|
How Adverum (ADVM) Stock Stands Out in a Strong Industry
|
|
Apr 3
|
Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround
|
|
Mar 27
|
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
|
|
Mar 20
|
Adverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial Adjustments
|
|
Mar 19
|
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
|
|
Mar 18
|
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
|
|
Feb 8
|
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
|